Sandoz launches generic Latisse

PRINCETON, N.J. — Sandoz on Wednesday launched its generic of Allergan’s Latisse (bimatoprost ophthalmic solution, 0.03%) in the United States. The medication is indicated to treat hypotrichosis of the eyelashes by stimulating growth, length, thickness and darkness. 

 

"The launch of bimatoprost is an important addition to our industry-leading portfolio of ophthalmic products,” Sandoz president Peter Goldschmidt said. “By expanding our ophthalmic offerings, Sandoz will increase patients’ access to a comprehensive range of quality medicines at affordable prices.” 

 

The drug had U.S. sales of about $75 million for the 12-month period ended October 2016.